These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 34773078)

  • 1. Development of an aerosol intervention for COVID-19 disease: Tolerability of soluble ACE2 (APN01) administered via nebulizer.
    Shoemaker RH; Panettieri RA; Libutti SK; Hochster HS; Watts NR; Wingfield PT; Starkl P; Pimenov L; Gawish R; Hladik A; Knapp S; Boring D; White JM; Lawrence Q; Boone J; Marshall JD; Matthews RL; Cholewa BD; Richig JW; Chen BT; McCormick DL; Gugensberger R; Höller S; Penninger JM; Wirnsberger G
    PLoS One; 2022; 17(7):e0271066. PubMed ID: 35816490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SARS-COV-2 Delta variant displays moderate resistance to neutralizing antibodies and spike protein properties of higher soluble ACE2 sensitivity, enhanced cleavage and fusogenic activity.
    Neerukonda SN; Vassell R; Lusvarghi S; Wang R; Echegaray F; Bentley L; Eakin AE; Erlandson KJ; Katzelnick LC; Weiss CD; Wang W
    bioRxiv; 2021 Nov; ():. PubMed ID: 34790980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peptides derived from the SARS-CoV-2 receptor binding motif bind to ACE2 but do not block ACE2-mediated host cell entry or pro-inflammatory cytokine induction.
    Mahindra A; Tejeda G; Rossi M; Janha O; Herbert I; Morris C; Morgan DC; Beattie W; Montezano AC; Hudson B; Tobin AB; Bhella D; Touyz RM; Jamieson AG; Baillie GS; Blair CM
    PLoS One; 2021; 16(11):e0260283. PubMed ID: 34793553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sex- and age-specific regulation of ACE2: Insights into severe COVID-19 susceptibility.
    Viveiros A; Gheblawi M; Aujla PK; Sosnowski DK; Seubert JM; Kassiri Z; Oudit GY
    J Mol Cell Cardiol; 2022 Mar; 164():13-16. PubMed ID: 34774871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Debulking SARS-CoV-2 in saliva using angiotensin converting enzyme 2 in chewing gum to decrease oral virus transmission and infection.
    Daniell H; Nair SK; Esmaeili N; Wakade G; Shahid N; Ganesan PK; Islam MR; Shepley-McTaggart A; Feng S; Gary EN; Ali AR; Nuth M; Cruz SN; Graham-Wooten J; Streatfield SJ; Montoya-Lopez R; Kaznica P; Mawson M; Green BJ; Ricciardi R; Milone M; Harty RN; Wang P; Weiner DB; Margulies KB; Collman RG
    Mol Ther; 2022 May; 30(5):1966-1978. PubMed ID: 34774754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Picomolar inhibition of SARS-CoV-2 variants of concern by an engineered ACE2-IgG4-Fc fusion protein.
    Svilenov HL; Sacherl J; Reiter A; Wolff LS; Cheng CC; Stern M; Grass V; Feuerherd M; Wachs FP; Simonavicius N; Pippig S; Wolschin F; Keppler OT; Buchner J; Brockmeyer C; Protzer U
    Antiviral Res; 2021 Dec; 196():105197. PubMed ID: 34774603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine.
    Gebre MS; Rauch S; Roth N; Yu J; Chandrashekar A; Mercado NB; He X; Liu J; McMahan K; Martinot A; Martinez DR; Giffin V; Hope D; Patel S; Sellers D; Sanborn O; Barrett J; Liu X; Cole AC; Pessaint L; Valentin D; Flinchbaugh Z; Yalley-Ogunro J; Muench J; Brown R; Cook A; Teow E; Andersen H; Lewis MG; Boon ACM; Baric RS; Mueller SO; Petsch B; Barouch DH
    Nature; 2022 Jan; 601(7893):410-414. PubMed ID: 34794169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoclonal Antibody Treatment of Breakthrough COVID-19 in Fully Vaccinated Individuals with High-Risk Comorbidities.
    Bierle DM; Ganesh R; Tulledge-Scheitel S; Hanson SN; Arndt LL; Wilker CG; Razonable RR
    J Infect Dis; 2022 Feb; 225(4):598-602. PubMed ID: 34791298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin II receptor I auto-antibodies following SARS-CoV-2 infection.
    Jiang Y; Duffy F; Hadlock J; Raappana A; Styrchak S; Beck I; Mast FD; Miller LR; Chour W; Houck J; Armistead B; Duvvuri VR; Yeung W; Haglund M; Wallner J; Wallick JA; Hardy S; Oldroyd A; Ko D; Gervassi A; Murray KM; Kaplan H; Aitchison JD; Heath JR; Sather DN; Goldman JD; Frenkel L; Harrington WE
    PLoS One; 2021; 16(11):e0259902. PubMed ID: 34788328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoclonal antibody treatment for COVID-19 in solid organ transplant recipients.
    Sarrell BA; Bloch K; El Chediak A; Kumm K; Tracy K; Forbes RC; Langone A; Thomas L; Schlendorf K; Trindade AJ; Perri R; Wright P; Concepcion BP
    Transpl Infect Dis; 2022 Feb; 24(1):e13759. PubMed ID: 34787345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SARS-CoV-2 infection and replication in human gastric organoids.
    Giobbe GG; Bonfante F; Jones BC; Gagliano O; Luni C; Zambaiti E; Perin S; Laterza C; Busslinger G; Stuart H; Pagliari M; Bortolami A; Mazzetto E; Manfredi A; Colantuono C; Di Filippo L; Pellegata AF; Panzarin V; Thapar N; Li VSW; Eaton S; Cacchiarelli D; Clevers H; Elvassore N; De Coppi P
    Nat Commun; 2021 Nov; 12(1):6610. PubMed ID: 34785679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SARS-CoV-2 inhibits induction of the MHC class I pathway by targeting the STAT1-IRF1-NLRC5 axis.
    Yoo JS; Sasaki M; Cho SX; Kasuga Y; Zhu B; Ouda R; Orba Y; de Figueiredo P; Sawa H; Kobayashi KS
    Nat Commun; 2021 Nov; 12(1):6602. PubMed ID: 34782627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. S Protein, ACE2 and Host Cell Proteases in SARS-CoV-2 Cell Entry and Infectivity; Is Soluble ACE2 a Two Blade Sword? A Narrative Review.
    Nejat R; Torshizi MF; Najafi DJ
    Vaccines (Basel); 2023 Jan; 11(2):. PubMed ID: 36851081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An update on angiotensin-converting enzyme 2 structure/functions, polymorphism, and duplicitous nature in the pathophysiology of coronavirus disease 2019: Implications for vascular and coagulation disease associated with severe acute respiratory syndrome coronavirus infection.
    Devaux CA; Camoin-Jau L
    Front Microbiol; 2022; 13():1042200. PubMed ID: 36519165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using host receptor as a decoy to treat COVID-19: a solution for immune escape?
    Huang KY; Lin MS; Yang PC
    EMBO Mol Med; 2022 Nov; 14(11):e16818. PubMed ID: 36256519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioengineered angiotensin-converting-enzyme-2: a potential therapeutic option against SARS-CoV-2 infection.
    Maiti BK
    J Hum Hypertens; 2022 May; 36(5):488-492. PubMed ID: 34773078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Race for ACE: Targeting Angiotensin-Converting Enzymes (ACE) in SARS-CoV-2 Infection.
    Schieffer E; Schieffer B
    J Renin Angiotensin Aldosterone Syst; 2022; 2022():2549063. PubMed ID: 35685188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ACE2 Shedding and the Role in COVID-19.
    Wang J; Zhao H; An Y
    Front Cell Infect Microbiol; 2021; 11():789180. PubMed ID: 35096642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of Angiotensin-Converting Enzyme 2: A Potential Target to Prevent COVID-19?
    Hu Y; Liu L; Lu X
    Front Endocrinol (Lausanne); 2021; 12():725967. PubMed ID: 34745001
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.